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Neural stem/progenitor cells hold valuable potential for the treatment of neurodegenerative disorders. The modulation of intrinsic 
growth factor expression, such as neurotrophins and their receptors, is a necessary step in achieving neural stem cells (NSCs) therapy. 
The statins have recently been reported to provide both anti‑inflammatory and neuroprotective effects. In the developing and mature 
nervous systems, neurotrophic factors are known to impact neuronal growth and survival. In this study, we investigated for a positive 
effect of lovastatin on the expression of neurotrophins in the neonatal rat hippocampus‑derived NSCs. NSCs were isolated and cultured 
up to passage three. To confirm cellular identity, immunocytochemical evaluation and flow cytometry analysis were performed using 
specific antibodies. To determine the optimum concentration of lovastatin, the MTT assay was used. Neurotrophin expression was 
evaluated using quantitative real‑time reverse transcription‑polymerase chain reaction (RT‑qPCR). Flow cytometry results demonstrated 
that NSCs were positive for nestin, a  marker for neural progenitor cells. An increase in cellular viability was observed with a  24  h 
exposure of lovastatin. Moreover, results showed an increase in mRNA expression for all neurotrophins compared to the control group. 
Taken together, the results of this study add to the growing body of literature on the neuroprotective effects of statins in neurological 
disorders. Lovastatin is a promising therapeutic agent for the treatment of neurodegenerative disorders.
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INTRODUCTION
Neurotrophins are comprised of a small family of 
dimeric proteins, which assist in differentiation and 
survival of peripheral and central neurons. They reg‑
ulate neurogenesis, synaptic strength, and plastici‑
ty (Ivanisevic and Saragovi, 2013), as well as neurons 
survival, development, and function in the vertebrate 
nervous system (Vilar and Mira, 2016). Nerve growth 
factor (NGF), the first described member of the neu‑
rotrophin family, is best known for its trophic role in 
the prevention of programmed cell death in the neuron 
populations of the peripheral nervous system (Frade 
and Barde, 1998). In 1982, researchers reported that 
a second member of the family of neurotrophic fac‑
tors, brain‑derived neurotrophic factor (BDNF), exert‑
ed a protective effect on the survival of specific dorsal 
root ganglion neurons, purified from pig brain (Barde 
et al., 1982). Other members of the neurotrophin fam‑
ily, including ciliary neurotrophic factor (CNTF), neu‑
rotrophin‑3 (NT‑3), glial cell line–derived neurotroph‑
ic factor (GDNF), and neurotrophin‑4 (NT‑4), have also 
been described with distinct trophic effects on differ‑
ent neuronal populations of the peripheral and central 
nervous system. CNTF is broadly studied and known to 
promote the survival of all classes of neurons (Dubovy 
et al., 2011). Statins are 3‑hydroxy‑3‑methylglutaryl 
coenzyme A (HMG‑CoA) reductase inhibitors, which are 
used to treat dyslipidemia and reduce the risks asso‑
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ciated with atherosclerosis. Statins have recently been 
considered as potential remedies for the treatment of 
various neurological disorders and increasing clinical 
studies are underway (Malfitano et al., 2014). Accord‑
ing to recent studies, the use of biomolecules with 
a positive impact on neurotrophic factors may reduce 
neuronal damage in neurodegenerative disorders (Lin 
et al., 2015; Razavi et al., 2015). In this study, we evalu‑
ated the effects of lovastatin on the expression of neu‑
rotrophins in neural stem cells and found the optimal 
concentration to induce such effects.
METHODS
Isolation and expansion of NSCs
NSCs were isolated from the hippocampus of three 
neonatal Wistar rats (5–10 days old) purchased from 
the Razi Vaccine and Serum Research Institute (Karaj, 
Iran). Briefly, under deep anesthesia by intraperito‑
neal injection of ketamine/xylazine (100 mg/kg and 
10 mg/kg, respectively), the brains were removed and 
the dissected hippocampi washed in the ice‑cold phos‑
phate‑buffered saline (PBS, Gibco), supplemented with 
4.5 g/L glucose. The collected tissues were homoge‑
nized with a scalpel and then dissociated using a di‑
gestion mixture of papain [2.5 U/ml] (Sigma‑Aldrich; 
Germany), dispase II [40 U/ml] (Sigma‑Aldrich; Germa‑
ny) and accutase [1 ml] (Invitrogen; Thermo Fisher Sci‑
entific, USA) for 30 min at the room temperature. The 
cell mixture was passed through a 70 µm cell strain‑
er (Falcon) and centrifuged for 10 min, at 1,000 g and 
4°C. Then, the pellets were washed in phosphate‑buff‑
ered saline. The cells were seeded in non‑adherent T25 
flasks in NSCs medium containing Dulbecco modified 
eagle medium/F‑12 (DMEM/F12) supplemented with 
2% B27 (Gibco; Thermo Fisher Scientific Inc.), 20 ng/ml 
basic fibroblast growth factor (bFGF; Invitrogen; Ther‑
mo Fisher Scientific Inc.), 20 ng/ml epidermal growth 
factor (EGF; Invitrogen; Thermo Fisher Scientific Inc.), 
100 U/ml penicillin and 100 mg/ml streptomycin (Sig‑
ma‑Aldrich; Merck KGaA), and then incubated at 37°C 
in 5% CO2 to form neurospheres for six days (Pall et al., 
2017). The medium was supplemented every two days. 
In the next step, the cells were dissociated enzymati‑
cally using trypsin‑EDTA (0.25%; Sigma‑Aldrich; Merck 
KGaA) and mechanically by pipetting to single cells. 
NSCs (105 cells/well) were suspended in DMEM/F12 
supplemented with 2% B27, 20 ng/ml bFGF, 20 ng/ml 
EGF and 3% fetal bovine serum (FBS; Gibco; Thermo 
Fisher Scientific Inc., Waltham, MA, USA) for one week 
(at 37˚C in 5% CO2) in 6‑well adherent plates coated 
with poly‑l‑lysine and cultured up to passage num‑
ber three. For identification of these cells, immuno‑
cytochemical evaluation, and flow cytometry analysis 
were performed using anti‑nestin monoclonal antibody 
(ab6142; 1:300; Abcam), followed by incubation with 
a fluorescein isothiocyanate (FITC)‑conjugated rabbit 
anti‑mouse antibody 1/300 (Millipore, Billerica, MA, 
USA, AP307F). Cells were cultured on cover slides and 
fixed in 3% paraformaldehyde for 20 minutes, followed 
by a permeabilization step in 100% methanol for 30 min 
at room temperature. Then cells were incubated with 
the primary antibody at 4°C overnight, and the next 
day secondary FITC‑conjugated for four hours. Ethid‑
ium bromide was used for 30 secs for nuclei counter‑
staining at room temperature. Images were captured 
with an Olympus BX51 fluorescence microscope (Olym‑
pus Corporation, Tokyo, Japan). All experimental pro‑
tocols were approved by the Zanjan University of Med‑
ical Sciences Ethics Committee. 
Lovastatin dose‑response 
The third‑passage of NSCs was cultured in 96‑well 
plates (5×104 cells/well) in DMEM/F12 medium supple‑
mented with 2% B27, 20 ng/ml bFGF and 20 ng/ml EGF 
for 24 h. The cells were treated with different concen‑
trations of lovastatin (C24H36O5 – PubChem) (2, 4, 6, 8 
and 10 µM) for the next 24 h, which was repeated every 
12 h. The NSCs without lovastatin treatment were used 
as the control group. Then, the cells were incubated 
with 1 mg/ml MTT (Sigma Aldrich, Germany) solution 
for four hours. The culture medium was removed and 
100 μl dimethyl sulfoxide added to each well to dissolve 
the formazan crystals. The amount of formazan was 
quantified at 570 nm using a microplate ELISA read‑
er. The relative cell viability in percentage (Han et al., 
2009) was calculated as: Relative cell viability = (A570 
of treated samples / A570 of untreated samples) × 100.
Cresyl violet staining
The ability of NSCs to differentiate into neuron‑like 
cells was evaluated by Nissl staining (0.1% cresyl vio‑
let). Briefly, the medium was aspirated and the cells 
were gently washed twice with phosphate‑buffered 
saline (PBS) and fixed with 4% paraformaldehyde for 
15 min at room temperature. Then, the fixation solu‑
tion was aspirated and the cell monolayer was gently 
washed with PBS twice. In the next step, PBS was re‑
moved from the cells and staining solution (0.5% cresyl 
violet) was added, followed by incubation at room tem‑
perature for 30 min. After washing with PBS, the cells 
were observed under light microscope (BX61; Olympus, 
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Tokyo, Japan) and the blue/violet colored cells were 
considered positive.
Real‑time RT‑qPCR
RT‑qPCR was carried out using extracted cDNA 
from control and treatment groups. Total RNA of hip‑
pocampal tissues was isolated by TRIzol® (Invitrogen/
Life Technologies). We used 1,000 ng of purified RNA 
to synthesize 20 µl of cDNA according to a Revert Aid™ 
First Strand cDNA Synthesis Kit (Fermentas, Germany). 
The cDNA was then used to quantify mRNA levels of 
the neurotrophins Bdnf, Gdnf, Cntf, Ngf, NT‑3 and NT‑4. 
Glyceraldehyde 3‑phosphate dehydrogenase (Gapdh) 
was used as the internal control for normalization. 
RT‑qPCR was conducted using primers shown in Ta‑
ble I. The PCR solution contained forward and reverse 
primers (200 nM each), cDNA (0.5 µl), SYBR® Green I 
(6.5 µl; Fermentas; Thermo Fisher Scientific, Inc.) and 
nuclease‑free water up to the final volume of 12.5 μl. 
The PCR reaction was repeated for 40 cycles, each cycle 
including 15 s in 95˚C followed by 1 min in 60˚C. Relative 
changes in target mRNA levels were determined using 
the ΔΔCq method (Livak and Schmittgen, 2001; Mosley 
and HogenEsch, 2017). The product size of the PCR was 
later verified by 2% agarose gel electrophoresis. The 
experiments were repeated three times.
Statistics
Statistical analyses were performed using SPSS 
software version 15 (IBM; Armonk, New York, United 
States). All data are presented as the mean ± standard 
error of mean (SEM) from independent experiments 
that were repeated three times. One‑way ANOVA and 
Tukey’s post hoc test were used for data comparisons 
between the groups. P values less than 0.05 were con‑
sidered significant.
RESULTS 
Neural stem cells culture
The results of the primary culture of NSCs are pre‑
sented in Fig. 1A‑C. The initial culture of NSCs isolated 
from the neonatal rat hippocampus appeared single and 
round with clear boundaries in the first 24 h (Fig. 1A). 
After 3 days, self‑renewing neuron‑like cells with mul‑
tipolar processes and growth cone‑like features were 
identified (Fig. 1B). After 3 passages (Fig. 1C) the cells 
were placed into uncoated 6‑well plates to allow neu‑
rosphere formation. After 24 h, small spheroids were 
observed (Fig. 1D). There was a statistically significant 
difference between groups as determined by one‑way 
ANOVA (F2,27=97.26, p<0.001). A Tukey’s post hoc test re‑
vealed that the average spheroid diameter significantly 
increased after 3 days (136.90 ± 9.94 µm, p<0.001) and 
6 days (224.30 ± 11.61 µm, p<0.001) compared to day one 
(47.40 ± 2.70 µm). There was also a significant difference 
between day 3 and day 6 (p<0.001) as shown in figures 
1D‑F and L. Moreover, with higher magnification it was 
observed that the cells separated from primary spher‑
oids can replicate and form new spheroids (Fig. 1F). The 
NSCs produced from spheroids were strongly positive 
for nestin (Fig. 1G and 1H) immunostaining. Flow cy‑
tometry confirmed that 77.50% NSCs were positive for 
nestin (Fig. 1N).
MTT assay 
The MTT assay was used to determine the highest 
tolerated dose of lovastatin for hippocampal derived 
Table I. Primer sequences and PCR parameters. Primers for amplification of target sequences and their Gen Bank accession number.
Gene Gene Accession no. Sense 5 → 3 Anti‑sense 5 → 3
NT‑3 NM_031073 GAGGGACCATTCGAGGTGAC CCAGGGACGTCGACATGAAG
NT‑4 NM_013184 ATCAGAGGACCCTGACTTAC GATACGGTGCTCAGGATAGA
BDNF NM_001270636.1 TTGAGCACGTGATCGAAGAG CTCCAGCAGAAAGAGCAGAG
GDNF NM_019139.1 CGGACGGGACTCTAAGATGA ATATTGGAGTCACTGGTCAGC
NGF NM_001277055.1 TCATCCACCCACCCAGTCTTCC TAATGTTCACCTCGCCCAGCAC
CNTF NM_013166.1 GAGCAAACACCTCTGACCCT CAACGATCAGTGCTTGCCAC
GAPDH NM_017008.4 TTGTCAGCAATGCATCCTGCAC GTCTGGGATGGAATTGTGAG
Primers were designed by Gene Runner 3.05 software (Product by: info@genfanavaran.com) NT‑3: Neurotrophin 3; NT‑4: Neurotrophin 4; Bdnf: Brain‑derived neurotrophic 
factor; Gdnf: Glial cell line‑derived neurotrophic factor; Ngf: Nerve growth factor; Cntf: Ciliary neurotrophic factor; Gapdh: Glyceraldehyde‑3‑phosphate dehydrogenase.
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NSCs. As shown in figure 1M, a gradual increase in con‑
centrations of lovastatin from 6 to 10 μM subsequent‑
ly decreased cell numbers in the cultures. The highest 
rate of cell proliferation was observed with 6 µM of lo‑
vastatin and a 24 h exposure (81.59% ± 2.44). There was 
a statistically significant difference between groups 
as determined by one‑way ANOVA (F4,35=4.38, p<0.006). 
A Tukey’s post hoc test revealed there is significant dif‑
ference between optimum (6 µM) and 10 µM concen‑
tration of lovastatin (63.89% ± 3.09, p<0.002). Lovasta‑
tin affected cell viability in a dose‑dependent manner, 
thus we chose 6 μM lovastatin as the optimum dose for 
further studies to avoid neurotoxic effects of higher 
concentrations (10 µM). In the time course of the ex‑
periment, incubation of NSCs with 6 μM lovastatin for 
24 h resulted in the retraction of the cell bodies and 
processes (Fig. 2A and 2B). Also, the treated cells were 
positive for Nissl bodies determined by cresyl violet dye 
(34.66% ± 5.61) (Fig. 2D). As shown in Fig. 2C, no cells 
were positive for Nissl staining in the control group. 
Gene expression
The changes in the mRNA levels of Bdnf, Gdnf, 
Cntf, Ngf, NT‑3 and NT‑4 were examined using RT‑qP‑
CR. The results of our study showed that lovastatin 
increased the expression of neurotrophins relative to 
the control group with a statistically significant dif‑
ference between mRNA level‑based gene expressions 
as determined by one‑way ANOVA (F5,30=22.36, p<0.001) 
(Fig. 3A). A Tukey’s post hoc test revealed that mRNA 
expression levels for GDNF significantly increased after 
lovastatin treatment (128.85 ± 16.71, p<0.001) compared 
to other genes. The mean fold‑changes for Bdnf, Gdnf, 
Cntf, Ngf, NT‑3 and NT‑4 genes were: 34.80 ± 3.23, 128.85 
Fig. 1. Representative photomicrograph of hippocampus‑derived NSCs, neurosphere diameters and dose‑response assay. Cell attachments of the freshly 
extracted NSCs (A), cells at passage 1 (day 7) (B), and passage 3 (day of 16) (C). (D), (E) and (F) represent floating neurospheres derived from neonate rat 
hippocampus (rosette like structures) after 1, 3 and 6 days, respectively. (G) represents immunostaining of Nestin (specific markers for neural stem/pro‑
genitor cells); the cells were immunostained with relevant primary antibodies and labeled with FITC‑conjugated secondary antibody (green color shows 
positive cells) and the red colors are ethidium bromide counterstaining of the nuclei. (H) represents phase contrast micrographs at the same field. (L) His‑
togram of neurosphere diameters at different time points; *represents the significant difference with day 6 (P<0.001, post‑hoc Tukey’s test); # represents 
the significance difference with day 3 (P<0.001, post‑hoc Tukey’s test). (M) MTT assay graphs represent dose‑response NSC viability at different concentra‑
tions of lovastatin (results show the mean % viability relative to 0 µM treated NSCs); *represents the significant difference with the 10 µM experimental 
group (p<0.002, post‑hoc Tukey’s test). (N) represents detection of nestin using flow cytometry analysis. Scale bars 200 μm at × 400 magnification. Each bar 
represents the average measurement from 5 replicates. The bars indicate the mean ± SEM. 
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± 16.71, 30.14 ± 3.55, 52.21 ± 6.74, 26.05 ± 3.56 and 42.29 
± 6.31, respectively. The induced NSCs expressed all as‑
sessed neurotrophins as detected by gel electrophore‑
sis (Fig. 3B).
DISCUSSION
The results of the present study showed that lovas‑
tatin induced expression of neurotrophic factors in the 
treated NSCs as compared to the control group. To our 
knowledge, this is the first study to demonstrate the 
increased release of neurotrophic factors from neu‑
ral stem cells following lovastatin treatment in‑vitro. 
Neurotrophic factors have been broadly investigated 
for their roles in supporting survival, proliferation and 
maturation of neural populations, leading to improved 
neural regeneration in neurodegenerative diseases, 
such as Alzheimer’s, Parkinson’s and Huntington’s dis‑
eases (Lin et al., 2015; Xiao and Le, 2016). The effects 
of neurotrophins are not limited to neurogenesis and 
axonal sprouting. It has also been shown that neuro‑
Fig. 2. Phase contrast images of the neuron‑like cells differentiation of NSCs using lovastatin. (A) and (B) indicate 0 µM and 6 µM lovastatin‑treated NSCs 
for 12 hours of incubation, respectively. Retraction of cell body and process formation are evident in the 6 µM lovastatin‑treated cells. (C) and (D) indicate 
the Nissl body staining using cresyl violet. (C) negative control (0 µM lovastatin‑treated NSCs), (D) positive control (6 µM lovastatin‑treated NSCs). Dark 
blue particles in the cytoplasm show Nissl bodies and the red and black arrows show positive and negative cells, respectively. Scale bars 200 μm at × 400 
magnification.
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trophins have distinct regulatory effects at various ex‑
citatory/inhibitory synapses and for survival of cells in 
the central nervous system (Quiroz et al., 2010). 
Lovastatin, an HMG‑CoA reductase inhibitor, has 
various pharmacological actions, including lowering 
cholesterol and reducing inflammation, as well as an‑
ticancer, antioxidant and, in particular, neuroprotec‑
tive effects (Nasiri et al., 2016; Yan et al., 2015). This 
drug has shown neuroprotective activity and easily 
permeates the blood‑brain barrier because of its li‑
pophilicity (Lin et al., 2015). Statins alter the fate of 
neural stem‑progenitor cells (NSPCs) in different ways 
and during differentiation may lead to the expression 
of mRNAs through a non‑CBP pathway (Carson et al., 
2018). Statins also have positive effects on NSPCs by in‑
creasing neurogenesis through the Wnt/beta‑catenin 
signaling pathway (Robin et al., 2014). As demonstrat‑
ed in animals, statins can produce significant toxicity 
at high doses (Hajar, 2011). In the present study, we 
demonstrated that increased concentrations of lovas‑
tatin lead to decreased cell viability. Other studies have 
reported that statins affect the G1 phase and alter neu‑
ral precursor cell divisions in a dose‑dependent man‑
ner (Carson et al., 2018). Statins are presumed to exert 
their neuroprotective effects by promoting the release 
of neurotrophic factors and inducing neurotrophic fac‑
tor gene expression, such as the BDNF (Roy et al., 2015). 
The results of this study simply and clearly add to 
the understanding of the mechanisms underlying the 
therapeutic potential of statins in neurological dis‑
orders found in previous studies (Rajanikant et al., 
2007; Malfitano et al., 2014). Our results showed that 
the expression of BDNF in the treated group increased 
by approximately 34 fold in comparison with the con‑
trol group. Most studies have investigated the effect 
of statins on Bdnf expression under in vivo condition. 
Roy et al. (2015) demonstrated that different statins 
up‑regulate Bdnf and NT‑3 in neurons, microglia and 
astrocytes. It has also been reported that treatment of 
rat primary microglial cultures with 20 μM simvasta‑
tin increases Bdnf expression (Churchward and Todd, 
2014). BDNF supports the survival of existing neurons 
and encourages the growth and differentiation of new 
neurons and synapses through axonal and dendritic 
sprouting (Kim et al., 2017). Chen et al. (2015) report‑
ed that neural plasticity was promoted by statin ther‑
apy through upregulation of Bdnf after stroke in mice. 
BDNF regulates neuronal survival, cell migration, and 
synaptic function. Thus, statins, along with increased 
Bdnf expression, can play an important role in improv‑
ing and restoring brain tissue after stroke (Chen et al., 
2005). Han et al. (2011) demonstrated the role of sim‑
vastatin on functional improvement after spinal cord 
injury in rat by upregulating the expression of Bdnf and 
Gdnf. It has been suggested that BDNF promotes the 
survival of subventricular zone neurons and differenti‑
ation of postnatal hippocampal stem cells. In our study, 
the results showed that lovastatin increased Bdnf mRNA 
levels relative to non‑treated NSCs. An increase of Gdnf 
mRNA expression was seen in our study. It was reported 
that simvastatin significantly increased the expression 
of Bdnf and Gdnf in the rat model of spinal cord injury 
Fig. 3. (A) Quantitative real‑time RT‑PCR results. All mRNA expression is presented as lovastatin‑treated NSCs relative to the control group (non‑treated 
NSCs) normalized to Gapdh mRNA amplification. (B) Expression of neurotrophic genes. L, Ct, T and NTC indicate the ladder (100 bp), NSCs treated with 
0 µM lovastatin, NSCs treated with 6 µM lovastatin and negative control (without cDNA), respectively. This is a pairwise comparison and the bars indicate 
the mean ± SEM. *represents the significant difference versus Gdnf genes (p<0.001, post‑hoc Tukey’s test).
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(Gao et al., 2015). GDNF plays an important role in the 
survival of neurons, in enhancing the remyelination of 
damaged axons and causes neuronal regeneration after 
spinal cord injury (SCI) (Razavi et al., 2017). 
Several studies have shown therapeutic effects of 
GDNF in various diseases of the central nervous sys‑
tem, such as Parkinson’s disease, stroke and epilepsy 
(Koppula et al., 2012; Zilliox et al., 2016). In rat models 
of SCI, the use of statins was associated with improved 
locomotor activity through up‑regulation of Gdnf, Bdnf 
and Vegf expression (Kahveci et al., 2014). In our study, 
treatment with lovastatin lead to a significant increase 
in Gdnf mRNA expression. Simvastatin has also recent‑
ly been demonstrated to improve peripheral nerve re‑
generation and functional recovery in an experimental 
model of sciatic damage that involves elevation of lev‑
els of Gdnf and several other growth factors (Guo et al., 
2018). Quantitative PCR results from the present study 
indicate that lovastatin also increased Cntf expression. 
CNTF is expressed mainly in glial cells as well as in 
neurons, and its cytoprotective effect appears to be ex‑
erted after stress or damage. CNTF has recently been 
used to treat patients with neurodegenerative diseases 
such as ALS (Purser et al., 2013). In this study, we found 
that treating NSCs with lovastatin led to an increase in 
Ngf mRNA expression. It has been reported that statins 
such as simvastatin and atorvastatin enhance expres‑
sion of growth factors (BDNF, VEGF and NGF) and ac‑
tivate the PI3K/Akt‑mediated signaling pathway after 
experimental intracerebral hemorrhage (Yang et al., 
2012). NGF is critical for the survival and maintenance 
of sympathetic and sensory neurons. We observed that 
lovastatin led to an increase in the expression of NT‑3 
and NT‑4, especially NT‑4. Statins have been reported 
to dose‑dependently up‑regulate Bdnf and NT‑3 mRNA 
expression in mouse primary astrocytes (Roy et al., 
2015). Statins were also shown to enhance expression 
of growth factors (BDNF, VEGF, and NGF) and activate 
the PI3K/Akt‑mediated signaling pathway after exper‑
imental intracerebral hemorrhage (Yang et al., 2012). 
NT‑3 belongs to the NGF family; it plays an essential 
role in cell survival, axonal growth and neuronal plas‑
ticity (Xu et al., 2002). It helps to support the survival 
and differentiation of existing neurons and encourag‑
es the growth and differentiation of new neurons and 
synapses. In‑vitro studies demonstrated that exoge‑
nous NT‐3 increased proliferation of neural crest and 
somite‑derived NSCs (Levenberg et al., 2005). Finally, 
there are limited studies on the role of statins in the al‑
teration of CNTF, NT‑3, and NT‑4 expression, making it 
hard to draw conclusions from our results. The most re‑
cently discovered member of this family is NT‑4, which 
plays a role in the survival and differentiation of verte‑
brate neurons (Proenca et al., 2016).
The mechanisms by which neurotrophins and growth 
factors determine cell fate is still not fully understood. 
In this study, the flow cytometry analyses showed 
77.50% of cells expressing nestin. This result may indi‑
cate contamination of primary cells isolated from brain 
tissue (the possible presence of mature astrocytes and 
microglia). Astrocytes were cultured under adherent 
culture conditions and mature astrocytes do not show 
nestin expression (Cho et al., 2013). The downregulation 
of nestin expression in astrocytes parallels the increase 
of glial fibrillary acidic protein (GFAP) in differentiating 
astrocytes (Cho et al., 2013). One of the limitations of 
this study is that the cells were not purified but brain 
cells can release neurotrophins and are sensitive to 
statin treatment both in vitro and in vivo (McFarland 
et al., 2014). Statins have been reported to upregulate 
Bdnf and NT‑3 in neurons, microglia and astrocytes (Roy 
et al., 2015). Additionally, due to scientific sanctions 
against Iran and limited financial resources to conduct 
this investigation, we did not perform post‑transcrip‑
tional analysis of the gene products using ELISA with 
antibodies. As a result of the sanctions, antibodies are 
difficult to obtain and very expensive. 
 Encouragingly, statins have been broadly identi‑
fied as possible preventative or treatment options in 
a number of neurological disorders, such as stroke, ep‑
ilepsy, depression, cancers and brain and spinal cord 
injuries. Results from preclinical animal models sug‑
gest that statins may be neuroprotective in response 
to acute brain injury and chronic neurodegenerative 
disorders (Roy et al., 2015). Our results, in summary, 
importantly add to the growing body of evidence on 
the neuroprotective effects of statins for neurological 
disorders and support that lovastatin is a promising 
therapeutic agent for the treatment of neurodegener‑
ative disorders. Future investigations are necessary to 
validate the conclusions drawn from this study examin‑
ing the underlying cellular and molecular mechanisms 
of neurotrophin regulation by statins.
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